{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:54:31Z","timestamp":1787018071054,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2018,4,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clinical trials have shown cardiovascular benefits and potential risks from sodium glucose cotransporter 2 inhibitors (SGLT2i). Trials may have limited ability to address individual end points or safety concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a population-based cohort study among patients with type 2 diabetes mellitus with established cardiovascular disease newly initiated on antihyperglycemic agents within the US Department of Defense Military Health System between April 1, 2013, and December 31, 2016. Incidence rates, hazard ratios (HRs), and 95% confidence intervals (CIs) for time to first composite end point of all-cause mortality and hospitalization for heart failure event, major adverse cardiovascular events (defined as all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke), and individual end points were evaluated using conditional Cox models comparing new SGLT2i users with other antihyperglycemic agents. The exploratory safety end point was below-knee lower extremity amputation. Intent-to-treat and on-treatment analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After propensity matching, 25\u2009258 patients were followed for a median of 1.6 years. Compared with non-SGLT2i, initiation of SGLT2i was associated with a lower rate of all-cause mortality and hospitalization for heart failure (1.73 versus 3.01 events per 100 person-years; HR, 0.57; 95% CI, 0.50\u20130.65) and major adverse cardiovascular events (2.31 versus 3.45 events per 100 person-years; HR, 0.67; 95% CI, 0.60\u20130.75). SGLT2i initiation was also associated with an \u22482-fold higher risk of below-knee lower extremity amputation (0.17 versus 0.09 events per 100 person-years; HR, 1.99; 95% CI, 1.12\u20133.51). Because of the disproportionate canagliflozin exposure in the database, the majority of amputations were observed on canagliflozin. Results were consistent in the on-treatment analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this high-risk cohort, initiation of SGLT2i was associated with lower risk of all-cause mortality, hospitalization for heart failure, and major adverse cardiovascular events and higher risk of below-knee lower extremity amputation. Findings underscore the potential benefit and risks to be aware of when initiating SGLT2i. It remains unclear whether the below-knee lower extremity amputation risk extends across the class of medication, because the study was not powered to make comparisons among individual treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.117.031227","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T10:05:11Z","timestamp":1510567511000},"page":"1450-1459","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":210,"title":["Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor"],"prefix":"10.1161","volume":"137","author":[{"given":"Jacob A.","family":"Udell","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardiovascular Division, Peter Munk Cardiac Centre, Toronto General Hospital and Women\u2019s College Hospital, University of Toronto, Canada (J.A.U.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville\/Raritan, NJ (Z.Y., N.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Rush","sequence":"additional","affiliation":[{"name":"Health ResearchTx, LLC, Trevose, PA (T.R., N.M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Sicignano","sequence":"additional","affiliation":[{"name":"Naval Medical Center, Portsmouth, VA (M.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Galitz","sequence":"additional","affiliation":[{"name":"Naval Medical Center, Portsmouth, VA (M.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville\/Raritan, NJ (Z.Y., N.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.03.410"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2017.01.009"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.633"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024764"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00044-3"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1701990"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30257-7"},{"key":"e_1_3_4_15_2","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) EMA\/PRAC\/637349\/2016. February 9 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002672\/WC500230719.pdf. Accessed November 10 2017."},{"key":"e_1_3_4_16_2","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. September 10 2015. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm461449.htm. Accessed November 10 2017."},{"key":"e_1_3_4_17_2","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana Invokamet) and dapagliflozin (Farxiga Xigduo XR). June 14 2016. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm. Accessed November 10 2017."},{"key":"e_1_3_4_18_2","unstructured":"U.S. Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana Invokamet Invokamet XR). May 16 2017. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm557507.htm. Accessed November 10 2017."},{"key":"e_1_3_4_19_2","unstructured":"National Diabetes Statistics Report. 2017. https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf. Accessed September 7 2017."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6217"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-12-00168"},{"key":"e_1_3_4_22_2","unstructured":"Health ResearchTx. U.S. Department of Defense Military Health System EASEL Dataset 4\/01\/2013-12\/31\/2016. http:\/\/www.healthresearchtx.com. Accessed November 10 2017."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2010.503544"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506115"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0573-0"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008862"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.117.031227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:51:31Z","timestamp":1715568691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.117.031227"}},"subtitle":["Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)"],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,4,3]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.117.031227"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.117.031227","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"2017-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}